Boston, Massachusetts, U.S., September 15, 2026
Xylo Bio, a clinical-stage biotechnology company developing novel neurotherapeutics for psychiatric and neurological disorders, has announced a major development milestone for XYL-1001, its investigational neuroplastogen being developed for major depressive disorder (MDD). The company reported that the first participants have been dosed in a Phase 1 clinical study of XYL-1001, marking Xylo Bio’s transition into the clinical stage. The randomized, double-blind, placebo-controlled study is being conducted in Australia and is designed to evaluate the candidate’s safety, tolerability, pharmacokinetics, and pharmacodynamic activity in healthy volunteers.
XYL-1001 Enters Clinical Development
The Phase 1 study will evaluate XYL-1001, a novel and selective 5-HT2A receptor agonist, through single ascending dose and multiple ascending dose cohorts. Researchers will assess how the investigational compound is tolerated at different dose levels while also examining its pharmacokinetic characteristics and biological activity. The trial incorporates translational biomarkers designed to characterize pharmacodynamic target engagement, providing information that could help guide subsequent clinical development decisions. The study represents an important step from preclinical research toward evaluating XYL-1001 in humans. Xylo Bio is developing XYL-1001 with the goal of activating the 5-HT2A receptor while avoiding the hallucinogenic effects associated with traditional psychedelic compounds that act through this receptor. According to the company, XYL-1001 is designed as a non-hallucinogenic neuroplastogen, potentially allowing development of a therapeutic approach that does not require the supervised dosing environment associated with certain psychedelic-based treatments. The company describes the candidate as, to its knowledge, the most selective 5-HT2A receptor agonist in this category.
Selective Neuroplastogen Targets Depression
Major depressive disorder remains an important area of drug development because existing treatments do not provide adequate benefit for every patient. Xylo Bio is pursuing a different therapeutic strategy by investigating whether selective activation of the 5-HT2A receptor can promote neuroplasticity without producing hallucinogenic effects. The company’s approach is focused on developing targeted neurotherapeutics that could potentially offer broader clinical utility and a more scalable treatment model. Preclinical studies of XYL-1001 have demonstrated 5-HT2A-dependent neuroplastic effects and activity in models of anxiety and depressive-like behaviors, according to the company. Importantly, Xylo Bio reported that these studies did not show signs of hallucinogenic-related behavior. However, these findings remain preclinical, and the ongoing Phase 1 study is necessary to determine whether the compound’s pharmacological characteristics and safety profile can translate into humans. XYL-1001 remains an investigational product and has not been approved by any regulatory authority.
Advertisement
Phase 1 Data Could Guide Future Development
The initial clinical study is expected to generate foundational information about the safety and pharmacology of XYL-1001. By combining conventional Phase 1 assessments with biomarker-based pharmacodynamic measurements, Xylo Bio aims to establish a clearer understanding of receptor engagement and biological effects before advancing the program into later-stage studies. The company is also highlighting its neuroplastogen platform at the 9th Neuropsychiatric Drug Development Summit in Boston, held September 15–17, 2026. Xylo Bio said its broader pipeline is focused on novel, non-hallucinogenic neuroplastogens engineered for oral delivery and scalable clinical utility. Its discovery programs use computational drug discovery approaches intended to identify compounds with receptor selectivity and neuroplastic effects relevant to neuropsychiatric disorders.
The initiation of the XYL-1001 Phase 1 study therefore represents an important development for Xylo Bio’s clinical pipeline. As the trial progresses, safety, tolerability, pharmacokinetic and pharmacodynamic data will help determine the next steps for clinical development in major depressive disorder. The program also reflects broader pharmaceutical research into new mechanisms for addressing treatment gaps in neuropsychiatric disease, while emphasizing the need for rigorous clinical evaluation of emerging neuroplastogen therapies.
Source: Xylo Bio press release
